These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22050397)

  • 21. Serotonin toxicity revisited.
    Schuman E
    Headache; 2009 May; 49(5):784-5. PubMed ID: 19456889
    [No Abstract]   [Full Text] [Related]  

  • 22. Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.
    Strouse TB; Kerrihard TN; Forscher CA; Zakowski P
    J Clin Psychopharmacol; 2006 Dec; 26(6):681-3. PubMed ID: 17110838
    [No Abstract]   [Full Text] [Related]  

  • 23. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum.
    Bonetto N; Santelli L; Battistin L; Cagnin A
    Cephalalgia; 2007 Dec; 27(12):1421-3. PubMed ID: 17868285
    [No Abstract]   [Full Text] [Related]  

  • 24. Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome.
    Sclar DA; Robison LM; Skaer TL
    Headache; 2008 Jan; 48(1):126-9. PubMed ID: 18005139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review.
    Gillman PK
    Headache; 2010 Feb; 50(2):264-72. PubMed ID: 19925619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug interactions with triptans : which are clinically significant?
    Rolan PE
    CNS Drugs; 2012 Nov; 26(11):949-57. PubMed ID: 23018546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.
    Evans RW; Tepper SJ; Shapiro RE; Sun-Edelstein C; Tietjen GE
    Headache; 2010 Jun; 50(6):1089-99. PubMed ID: 20618823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports.
    Evans RW
    MedGenMed; 2007 Sep; 9(3):48. PubMed ID: 18092054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin Syndrome With the Concomitant Use of Triptans and SSRIs/Serotonergic Medications: Is It Time to Revisit FDA Warning?
    Mansuri Z; Adnan M; Shah B; Trivedi C; Vadukapuram R; Patel S; Yadav G; Srinivas S; Ansari M; Makani R; Baweja R; Reddy A
    J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):199-200. PubMed ID: 38227629
    [No Abstract]   [Full Text] [Related]  

  • 30. Moclobemide and the risk of serotonin toxicity (or serotonin syndrome).
    Gillman K
    CNS Drug Rev; 2004; 10(1):83-5; author reply 86-8. PubMed ID: 15046013
    [No Abstract]   [Full Text] [Related]  

  • 31. Serotonin syndrome resulting from drug interactions.
    Chan BS; Graudins A; Whyte IM; Dawson AH; Braitberg G; Duggin GG
    Med J Aust; 1998 Nov; 169(10):523-5. PubMed ID: 9861909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report.
    Boutilier AS; Gardner DM
    J Clin Pharm Ther; 2003 Feb; 28(1):69-72. PubMed ID: 12605621
    [No Abstract]   [Full Text] [Related]  

  • 33. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome.
    Sclar DA; Robison LM; Castillo LV; Schmidt JM; Bowen KA; Oganov AM; Skaer TL; Kogut SJ
    Headache; 2012 Feb; 52(2):198-203. PubMed ID: 22289074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sertraline-induced serotonin syndrome followed by mirtazapine reaction.
    Butler MC; Di Battista M; Warden M
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1128-9. PubMed ID: 20430060
    [No Abstract]   [Full Text] [Related]  

  • 35. Serotonin syndrome with mirtazapine-fluoxetine combination.
    Benazzi F
    Int J Geriatr Psychiatry; 1998 Jul; 13(7):495-6. PubMed ID: 9695042
    [No Abstract]   [Full Text] [Related]  

  • 36. Unusual & serious adverse effects of SSRIs: recognition & management.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2007 Mar; 45(3):15-8. PubMed ID: 17396714
    [No Abstract]   [Full Text] [Related]  

  • 37. Serotonin Syndrome After an Alcohol Intake in a Patient Treated With Escitalopram and Clomipramine.
    Suzuki A; Otani K
    Clin Neuropharmacol; 2019; 42(3):103-104. PubMed ID: 30844852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.
    Abadie D; Rousseau V; Logerot S; Cottin J; Montastruc JL; Montastruc F
    J Clin Psychopharmacol; 2015 Aug; 35(4):382-8. PubMed ID: 26082973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The serotonin syndrome.
    Gnanadesigan N; Espinoza RT; Smith RL
    N Engl J Med; 2005 Jun; 352(23):2454-6; author reply 2454-6. PubMed ID: 15948273
    [No Abstract]   [Full Text] [Related]  

  • 40. Serotonin discontinuation syndrome: does it really exist?
    Nuss S; Kincaid CR
    W V Med J; 2000; 96(2):405-7. PubMed ID: 10771628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.